HERON THERAPEUTICS, INC. /DE/(HRTX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

HERON THERAPEUTICS, INC. /DE/ (HRTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HRTX at 24.7/100 on a 32-signal composite quality model, placing it at rank #2,684 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.9) and profitability (14.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HERON THERAPEUTICS, INC. /DE/ reports quarterly revenue of $37.7M, net income of $-5.5M, free cash flow of $-2.4M. Top institutional holders of HRTX by reported 13-F value include Rubric Capital Management, Clearline Capital, BlackRock, based on the most recent SEC filings. HRTX trades on the Nasdaq exchange and files with the SEC under CIK 818033. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HERON THERAPEUTICS, INC. /DE/ directly from SEC EDGAR.